Impact of a pharmaceutical care programme on health-related quality of life among women with epilepsy: A randomised controlled trial (IPHIWWE study)

Health and Quality of Life Outcomes

Volumn 12, Issue 1, 2014, Pages

  Losada Camacho, Martha ^a   Guerrero Pabon, Mario F ^a   Garcia Delgado, Pilar ^b   Martínez Martinez, Fernando ^b  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

Epilepsy; Patient reported outcomes (PROs); Pharmaceutical care; Quality of life; Randomised controlled trial; Women with epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; LEVETIRACETAM;

ADULT; AGED; ARTICLE; CES D QUESTIONNAIRE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG MONITORING; EPILEPSY; FEMALE; FOLLOW UP; HAYNES SACKETT TEST; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; INTERVIEW; LIVERPOOL AEP QUESTIONNAIRE; MAJOR CLINICAL STUDY; MORISKI GREEN TEST; PARALLEL DESIGN; PHARMACEUTICAL CARE; QOLIE 31 SCORE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEIZURE; TREATMENT RESPONSE; ADOLESCENT; HEALTH STATUS; MIDDLE AGED; OUTCOME ASSESSMENT; PATIENT EDUCATION; PHARMACY; PROCEDURES; PSYCHOLOGY; RISK; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; EPILEPSY; FEMALE; HEALTH STATUS; HUMANS; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PATIENT OUTCOME ASSESSMENT; PHARMACEUTICAL SERVICES; QUALITY OF LIFE; RISK; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84988353729     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/s12955-014-0162-8     Document Type: Article

References (41)

1. Gómez-Arias B, Crail-Meléndez D, López-Zapata R, Martínez-Juárez IE: Severity of anxiety and depression are related to a higher perception of adverse effects of antiepileptic drugs. Seizure 2012, 21(8):588-594.
2. Sahota P, Prabhakar S, Kharbanda PS, Bhansali A, Jain V, Das CP, Modi M: Seizure type, antiepileptic drugs, and reproductive endocrine dysfunction in Indian women with epilepsy: a cross-sectional study. Epilepsia 2008, 49(12):2069-2077.
3. Mei PF, Montenegro MA, Guerreiro MM, Guerreiro CAM: Pharmacovigilance in epileptic patients using antiepileptic drugs. Arq Neuropsiquiatr 2006, 64(2-A):198-201.
4. Almeida Souza Tedrus GM, Corrêa Fonseca L, Marin Carvalho R: Epilepsy and quality of life: socio-demographic and clinical aspects, and psychiatric co-morbidity. Arq Neuropsiquiatr 2013, 71(6):385-391.
5. Alanis-Guevara I, Peña E, Corona T, López-Ayala T, López-Mesa E, López-Gómez M: Sleep disturbances, socioeconomic status, and seizure control as main predictors of quality of life in epilepsy. Epilepsy Behav 2005, 7:481-485.
6. Yue L, Yu PM, Zhao DH, Wu DY, Zhu GX, Wu XY, Hong Z: Determinants of quality of life in people with epilepsy and their gender differences. Epilepsy Behav 2011, 22:692-696.
7. Canuet L, Ishii R, Iwase M, Ikesawa K, Kurimoto R, Azechi M, Takahashi H, Nakahashi T, Teshima Y, Takeda M: Factors associated with impaired quality of life in younger and older adults with epilepsy. Epilepsy Res 2009, 83:58-65.
8. Szaflarski JP, Szaflarski M: Seisure disorders, depression and health-related quality of life. Epilepsy Behav 2004, 5(1):50-57.
9. Hermann BP, Vickrey B, Hays RD, Cramer J, Devinsky O, Meador K, Perrine K, Myers LW, Ellison GW: A comparison of health-related quality of life in patients with epilepsy, diabetes and multiple sclerosis. Epilepsy Res 1996, 25:113-118.
10. Norsa'adah B, Zainab J, Knight A: The quality of life of people with epilepsy at a tertiary referral centre in Malaysia. Health Qual Life Outcomes 2013, 11:143.
11. May TW, Pfafflin M, Coban I, Schmitz B: Frauen und epilepsie: befürchtungen, wissen, beratungsbedarf. Nervenarzt 2009, 80:174-183.
12. European Declaration on Epilepsy. Heidelberg. [http://www.who.int/mental_health/media/en/82.pdf]
13. World Health Organization: El papel del farmacéutico en el sistema de atención en salud. Informe de la reunión de la Organización Mundial de la Salud, Tokyo 1993. Ars Pharmaceutica 1995, 36:285-292.
14. Hepler CD, Strand LM: Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990, 47:533-543.
15. Mahmann C, Radziwill R, Klotz JM, Jacobs AH: Health-related quality of life after isquemic stroke: the impact of pharmaceutical interventions on drug therapy (pharmaceutical care concept). Health Qual Life Outcomes 2010, 8:59 [http://www.hqlo.com/content/8/1/59]
16. Nixon A, Kerr C, Breheny K, Wild D: Patient Reported Outcome (PRO) assessment in epilepsy: a review of epilepsy-specific PROs according to the Food and Drug Administration (FDA) regulatory requirements. Health Qual Life Outcomes 2013, 11:38.
17. Koshy S: Role of pharmacists in the management of patients with epilepsy. Int J Pharm Pract 2011, 20:65-68.
18. Weil S, Deppe C, Noachtar S: The treatment of women with epilepsy. Dtsch Arztebl Int 2010, 107(45):787-793.
19. Sabater D, Silva MM, Faus MJ: Método Dáder: guía de seguimiento farmacoterapéutico. 3rd edition. La Gráfica S.C.And Granada: Granada; 2007.
20. Campos MR: Cómo afrontar la epilepsia: una guía para pacientes y familiares. Madrid: Entheos; 2005.
21. Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E: Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008, 49(7):1239-1276.
22. Torres X, Arroyo S, Araya S, De Pablo J: Adaptación del Quality-of-Life in Epilepsy Inventory (QOLIE-31): traducción, validez y fiabilidad. Rev Psiquiatría Fac Med Barna 2000, 27(7):406-413.
23. Vickrey B, Perrine K, Hays R, Hermann BP, Cramer JA, Meador KJ, Devinsky O: Quality of Life in Epilepsy QOLIE-31 (version 1.0): Scoring Manual and Patient Inventory. Santa Monica, CA: RAND; 1993 [http://www.rand.org/content/dam/rand/www/external/health/surveys_tools/qolie/qolie31_scoring.pdf]
24. Cramer J, Brandenburg NA, Xu X, Vera-Llonch M, Oster G: The impact of seizures and adverse effects on global health ratings. Epilepsy Behav 2007, 11(2):179-184.
25. Carreño M, Donaire A, Falip M, Maestro I, Fernández S, Gil A, Serratosa J, Salas J, Viteri C, Llorens J, Baró E: Validation of the Spanish version of the Liverpool Adverse Events Profile in patients with epilepsy. Epilepsy Behav 2009, 15:154-159.
26. Gilliam F, Carter J, Vahle V: Tolerability of antiseizure medications: implications for health outcomes. Neurology 2004, 63(Suppl. 4):S9-S12.
27. Campo-Arias A, Díaz-Martínez LA, Rueda-Jaimes GE, Cadena-Afanador LP, Hernández NL: Psychometric properties of the CES-D scale among Colombian adults from the general population. Rev Colomb Psiquiat 2007, 36(4):664-674.
28. Cramer J, Blum D, Reed M, Fanning K: The influence of comorbid depression on quality of life for people with epilepsy. Epilepsy Behav 2003, 4(5):515-521.
29. Haynes RB, Taylor DW, Sackett DL (Eds): Compliance in Health Care. Baltimore: Johns Hopkins University Press; 1979.
30. Morisky DE, Green LW, Levine DM: Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986, 24:67-74.
31. Shaafi Sheida SH: Quality of life in the epileptic patients. Eur Psychiatry 2008, 23(Suppl 2):S 395.
32. Losada-Camacho M: Preliminary results of a pharmacotherapeutic follow-up program in women with epilepsy in Bogotá, Colombia. Vitae 2011, 18(Suppl. 1):S 49-S 50.
33. The R Foundation for Statistical Computing. R version 3.0.1 (2013-05-16). Copyright (C) 2010. ISBN 3-900051-07-0
34. Cramer JA, Hammer AE, Kustrab RP: Quality of life improvement with conversion to lamotrigine monotherapy. Epilepsy Behav 2004, 5:224-230.
35. Borghs S, De la Loge C, Cramer JA: Defining minimally important change in QOLIE-31 scores: estimates from three placebo-controlled lacosamide trials in patients with partial-onset seizures. Epilepsy Behav 2012, 23:230-234.
36. Miranda G, Martínez FN, Arceo ME: La calidad de vida de los pacientes epilépticos determinada por la aplicación de la escala QOLIE-31. Neurol Neurocir Psiquiat 2007, 40(2):50-55.
37. Birbeck GL, Hays RD, Cui X, Vickrey BG: Seizure reduction and quality of life improvements in people with epilepsy. Epilepsia 2002, 43(5):535-538.
38. Helde G, Bovin G, Brathen G, Brodtkorb E: A structured, nurse-led intervention program improves quality of life in patients with epilepsy: a randomized, controlled trial. Epilepsy Behav 2005, 7:451-457.
39. Wiebe S, Matijevic S, Eliasziw M, Derry PA: Clinically important change in quality of life in epilepsy. J Neurol Neurosurg Psychiatry 2002, 73:116-120.
40. Kanjanasilp J, Preechagoon Y, Kaewvichit S, Richards RME: Pharmaceutical care improved outcomes in epileptic patients. CMU J Nat Sci 2008, 7(1):33-45.
41. Fogg A, Staufenberg EF, Small I, Bhattacharya D: An exploratory study of primary care pharmacist-led epilepsy consultations. Int J Pharm Pract 2012, 20:294-302.